Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16963708 | 0.89 | SCN9A (0.50) | SCN9AKCNH2SCN5AMLYCDEPHX2 | |
| SCHEMBL840824 | 0.82 | P4HTM (0.51) | SCN9AKCNH2SCN5AKDM4EEPHX2 | |
| SCHEMBL16964471 | 0.81 | EPHX2 (0.47) | SCN9AKCNH2SCN5AMLYCDKDM4E | |
| SCHEMBL839676 | 0.81 | MAPK1 (0.57) | SCN9AKCNH2SCN5AMLYCDKDM4E | |
| SCHEMBL3668875 | 0.81 | SCN9A (0.47) | SCN9AKCNH2SCN5AMLYCDEPHX2 | |
| SCHEMBL16964303 | 0.81 | MLYCD (0.58) | MLYCDEPHX2 | |
| SCHEMBL16964682 | 0.80 | RAB9A (0.60) | EPHX2 | |
| SCHEMBL16964674 | 0.74 | ALDH1A1 (0.47) | SCN9AKCNH2SCN5AKDM4E | |
| SCHEMBL18359001 | 0.74 | LMNA (0.62) | MLYCD | |
| SCHEMBL841772 | 0.74 | KCNH2 (0.57) | SCN9AKCNH2SCN5AKDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| US-9920042-B2 | Compounds for use in the treatment of mycobacterial infections | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2018-03-20 | — | — | US | disclosed |
| EP-2900638-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) | 2017-01-04 | — | — | EP | disclosed |
| EP-2900638-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-08-13 | — | — | US | disclosed |
| EP-2900638-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Université de Droit et de la Santé de Lille 2 (FR) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225388-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | C5, ALK, TYR | SCN9A 3729/4885KCNH2 2242/4885SCN5A 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.